SCHEMBL3584501

SCHEMBL3584501

CCOC(=O)C1CCCc2sc(-c3ccc(OCCCCl)cc3)nc21

nearest known ligand 0.42

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 12/20 0.42
PPARD Q03181 10/20 0.42
HRH3 Q9Y5N1 2/20 0.39
PPARG P37231 2/20 0.39
PTPN11 Q06124 1/20 0.38
ALDH1A1 P00352 3/20 0.36
KDM4E B2RXH2 2/20 0.36
KCNH2 Q12809 2/20 0.36
TP53 P04637 1/20 0.36
HSD17B10 Q99714 1/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3568521 0.94 PPARA (0.41) PPARAPPARDHRH3PPARGPTPN11
SCHEMBL3575263 0.87 PPARA (0.47) PPARAPPARDHRH3PPARG
SCHEMBL3575022 0.85 HRH3 (0.56) HRH3KCNH2
SCHEMBL13647423 0.84 TRPM8 (0.46) ALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL3921554 0.81 MEN1 (0.51) PPARAPPARDPPARGALDH1A1KDM4E
SCHEMBL3580295 0.81 PPARA (0.46) PPARAPPARDHRH3PPARGALDH1A1
SCHEMBL3578704 0.81 PPARA (0.44) PPARAPPARDPPARG
SCHEMBL3584189 0.81 HRH3 (0.57) HRH3KCNH2
SCHEMBL3582668 0.80 PPARA (0.43) PPARAPPARDHRH3PPARG
SCHEMBL13542098 0.77 PPARA (0.40) PPARAPPARDHRH3PPARGSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106745722-B Mobile tunnel type anaerobic tank supporting device and working method thereof 徐州腾睿智能装备有限公司 2020-09-15 CN disclosed
US-20100009969-A1 Fused Oxazoles & Thiazoles As Histamine H3- Receptor Ligands UCB PHARMA, S.A. (BE) 2010-01-14 US disclosed
US-20100009969-A1 Fused Oxazoles & Thiazoles As Histamine H3- Receptor Ligands UCB PHARMA, S.A. (BE) 2010-01-14 US disclosed
US-20100009969-A1 Fused Oxazoles & Thiazoles As Histamine H3- Receptor Ligands UCB PHARMA, S.A. (BE) 2010-01-14 US disclosed
EP-2049548-A1 FUSED OXAZOLES & THIAZOLES AS HISTAMINE H3- RECEPTOR LIGANDS UCB Pharma, S.A. (BE) 2009-04-22 EP disclosed
WO-2008012010-A1 FUSED OXAZOLES & THIAZOLES AS HISTAMINE H3- RECEPTOR LIGANDS UCB PHARMA, S.A. (BE) 2008-01-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100009969-A1 Fused Oxazoles & Thiazoles As Histamine H3- Receptor Ligands HRH3, HRH4, HRH2 PPARA 1138/4885PPARD 1213/4885HRH3 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.